News

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...